Yehuda Handelsman
Overview
Explore the profile of Yehuda Handelsman including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
145
Citations
5555
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Miller M, Tokgozoglu L, Parhofer K, Handelsman Y, Leiter L, Landmesser U, et al.
Expert Rev Cardiovasc Ther
. 2022 Jul;
20(8):609-625.
PMID: 35876118
Introduction: REDUCE-IT demonstrated that adding 4 g/day of icosapent ethyl (IPE; purified ethyl ester of eicosapentaenoic acid [EPA]) to statins substantially reduced cardiovascular disease (CVD) events, with few adverse effects....
12.
Handelsman Y, Bunch T, Rodbard H, Steinberg B, Thind M, Bigot G, et al.
J Diabetes Complications
. 2022 Jun;
36(7):108227.
PMID: 35717354
Aim: This post hoc analysis evaluated efficacy and safety of dronedarone in atrial fibrillation (AF) and atrial flutter (AFL) patients with/without diabetes. Methods: Patients were categorized according to baseline diabetes...
13.
Handelsman Y, Anderson J, Bakris G, Ballantyne C, Beckman J, Bhatt D, et al.
J Diabetes Complications
. 2021 Dec;
36(2):108101.
PMID: 34922811
Type 2 diabetes (T2D), chronic kidney disease (CKD), atherosclerotic cardiovascular disease (ASCVD), and heart failure (HF)-along with their associated risk factors-have overlapping etiologies, and two or more of these conditions...
14.
Bloomgarden Z, Handelsman Y
Am J Prev Cardiol
. 2021 Jul;
1:100007.
PMID: 34327450
No abstract available.
15.
Grunberger G, Sherr J, Allende M, Blevins T, Bode B, Handelsman Y, et al.
Endocr Pract
. 2021 Jun;
27(6):505-537.
PMID: 34116789
Objective: To provide evidence-based recommendations regarding the use of advanced technology in the management of persons with diabetes mellitus to clinicians, diabetes-care teams, health care professionals, and other stakeholders. Methods:...
16.
Handelsman Y, Jellinger P, Guerin C, Bloomgarden Z, Brinton E, Budoff M, et al.
Endocr Pract
. 2021 Jan;
26(10):1196-1224.
PMID: 33471721
The treatment of lipid disorders begins with lifestyle therapy to improve nutrition, physical activity, weight, and other factors that affect lipids. Secondary causes of lipid disorders should be addressed, and...
17.
Duprez D, Handelsman Y, Koren M
Vasc Health Risk Manag
. 2020 Oct;
16:403-418.
PMID: 33116551
Cardiovascular (CV) disease remains the leading cause of morbidity and mortality worldwide and poses an ongoing challenge with the aging population. Elevated low-density lipoprotein cholesterol (LDL-C) is an established risk...
18.
Khan M, Fonarow G, McGuire D, Hernandez A, Vaduganathan M, Rosenstock J, et al.
Circulation
. 2020 Sep;
142(12):1205-1218.
PMID: 32955939
With worsening epidemiological trends for both the incidence and prevalence of type 2 diabetes mellitus (T2DM) and heart failure (HF) worldwide, it is critical to implement optimal prevention and treatment...
19.
Handelsman Y, Bloomgarden Z
J Diabetes
. 2020 Jun;
12(9):630-632.
PMID: 32573096
No abstract available.
20.
Garber A, Handelsman Y, Grunberger G, Einhorn D, Abrahamson M, Barzilay J, et al.
Endocr Pract
. 2020 Feb;
26(1):107-139.
PMID: 32022600
No abstract available.